Akums has executed a Framework Agreement on 22nd August, 2025 with Government of the Republic of Zambia to establish a local manufacturing facility in Zambia

  • Akums generates ~3/4th revenue from domestic CDMO, which is 3x compared to next largest player
  • 2x capacity of the next largest player; plan to further augment capacity in complex dosage forms
  • 95% Domestic Revenue
  • 272 Cr. Capex (1,280 Cr. in last 5 years)
  • Deep and long lasting relationships with 1,400+ clients and 1,800+ suppliers
  • 11 CDMO manufacturing facilities catering to 60+ dosage forms
  • 970+ DCGI products approvals, 200+ first in India products, 6 granted patents, 3 R&D centers (2 DSIR approved)
  • 350+ regulatory / client audits in FY25; EUGMP accredited facilities, 2,000+ employees in quality function
  • Managing Directors’ Message Dear Investors It gives us immense pleasure in declaring the Q4 and full year FY25 results of your company. While your company started its journey in 2004, FY25 will remain etched in its memories as it got listed on the stock exchanges on 6th Aug’24. We once again extend our sincere gratitude to all stakeholders and remain committed to creating long term shareholder value. As you are aware that FY 2025 has been a year of significant volatilities. For our industry i.e. domestic pharma, we witnessed significant price erosion in APIs as well as muted volumes. This impacted the core CDMO business as well as further delayed the turnaround of the API business. This resulted in flat revenues of your company.
  • However, despite these headwinds, Akums’ grit and spirit shone through and we managed to maintain our margins, generated healthy cash flows, increased our R&D spend and continued adding growth levers. We launched 31 DCGI products, as we continue to offer niche portfolio to our partners. . - Sanjeev Jain & Sandeep Jain We took noteworthy steps towards becoming a global CDMO by signing an approx. EUR 200 Mn contract with a global pharma company. We have already received part consideration of EUR 100 Mn in April 2025. The supplies for this will commence in 2027. Your company also operationalized a new injectable facility which will further cement our sterile drug leadership in India. These are exciting times as we continue to build a global pharmaceutical company 
  • Akums  has executed a Framework Agreement on 22nd August, 2025 with Government of the Republic of Zambia  to establish a local manufacturing facility in Zambia


  • Akums  has executed a Framework Agreement on 22nd August, 2025 with Government of the Republic of Zambia  to establish a local manufacturing facility in Zambia and to undertake the manufacturing and supply of Medicines in Zambia, with the objective of supporting GRZ national health programs and enhancing local production capabilities in Zambia. 
  • The facility, in the future, also plans to export to neighboring countries including, but not limited to, Zimbabwe, Namibia, Botswana, Malawi, Tanzania, Mozambique etc. 
  • This Project shall be implemented through incorporation of a new joint venture company in Zambia in which Akums will be a majority partner owning 51% stake and a nominated Zambian state instrumentality owning 49% stake. 
  • The facility is expected to commence manufacturing in 2028. The facility plans to manufacture general oral solids, liquids, injectables as well as beta-lactam products.
  • Akums a leading contract development and manufacturing company in India, engaged in the development and manufacture of pharmaceutical products across a wide range of therapeutic areas, and is recognized for its contribution to pharmaceutical innovation and excellence. GRZ has identified the need to establish a local manufacturing base to ensure substantial access to essential medicines and medical supplies, promote economic growth and contribute to the improvement of the healthcare infrastructure in the Republic of Zambia. GRZ entered into a Framework Agreement with Akums to facilitate the collaboration for the establishment of a manufacturing facility in Zambia for essential pharmaceutical products. Pursuant to the Framework Agreement, the GRZ has nominated Zambian Partner to act as its implementing partner for the formation and operation of a joint venture with the Akums. 
    • a) Akums will hold 51% stake in JV Company, along with certain Affirmative Voting Matters. 
    • b) Govt. of Zambia, either directly or through its Agency shall place Purchase Order of value of not less than USD 25 million (USD Twenty-Five Million) per annum from Akums. 
    • c) In furtherance of this collaboration, Akums has agreed to provide its proprietary technology, know-how, and technical expertise to the JV, and the Parties intend to enter into a separate Technology Transfer Agreement 

Akums Drugs: Down 30%

  • CDMO is the biggest theme; select companies can grow 5 times in next 10 years: Madhusudan Kela
  • The Delhi-based contract development and manufacturing organisation (CDMO) 
  • Sandeep Jain, Managing Director of Akums Drugs said he expects the company's revenue to remain flattish for FY25. 
  • However, he will be able to maintain the margin in the CDMO business at around 15%.
  • About 78% of Akums' total revenue comes from the CDMO business.
  • Exports contribute around 5% of the company’s total revenue, and Jain said the aim is to maintain this level.
  • The company is also putting substantial effort into its marketing business to drive growth across other segments.
  • Akums is a pharmaceutical CDMO offering a comprehensive range of pharmaceutical products and services in India and overseas. 
  • The company has the largest capacity in the country. Its capacity utilisation stood at 40%, and can scale up to 60%.

 Thank you for contacting Rounaq! Please let us know how we can help you. 

Whatsapp: 7838491131

SEBI registered RA : Rounaq Bakshi
Waheguru

Comments

Post a Comment

Popular posts from this blog

Transcript of NMDC Limited post Q4 & FY 2024-25 Results

Image
Transcript of NMDC Limited post Q4 & FY 2024-25 Results Growth in PAT on an annual or a year-on-year 12-month basis of around 19% and PBT after exceptional item of around 16% Gold operations in Legacy, the first year was have also stabilized Legacy in the last 2 months, 3 months.  And hopefully, in this financial year, Legacy would also be showing good profits IMPORTS India which imports around 55 million, 60 million tons is likely to go up to 150 million to 160 million tons of import for India in terms of coking coal.  Have entered into arrangement with SAIL 60% of total sales as of date is routed through SAIL because send it to their stocking yard.  So based on the user charge, they also market mmdc products 40% still Nmdc market directly in terms of HR coils 2025 year will be much more substantially action packed in terms of NMDC Open new mines within India, coal and iron ore Outside India, we hope to acquire a few mines.  This will be a year where it will be ...
Read more

Looking to park some excess funds for the short term.?

Image
Looking to park some excess funds for the short term.  LiquidBeES by Nippon - has been the default choice for years. But lately, it’s become muscle memory to run everything past ChatGPT.  Just a quick: “Is there a better option than LiquidBeES?” It turns out, there is.  LIQUIDCASE by Zerodha AMC.  Difference was not subtle and decision was easier : - Expense ratio: Less than half of LiquidBeES - Net returns: ~6.2% vs ~5.7% (1-year annualized) - Same safety, same liquidity - AUM already >1/3rd of LiquidBeES in record time This is how discovery is changing. And this is how smart products go viral. Zerodha didn’t try to educate the market.  Discovery is no longer driven by ads or advisors.  It’s driven by habit, trust, and tools like ChatGPT. And when you get it right, traction follows fast. I won’t be surprised if LIQUIDCASE overtakes LiquidBeES in under 18 months. Thank you for contacting Rounaq! Please let us know how we can help you.  About me :...
Read more

𝐖𝐡𝐲 𝐃𝐨 𝐍𝐑𝐈𝐬 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚?

Image
  𝐖𝐡𝐲 𝐃𝐨 𝐍𝐑𝐈𝐬 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐈𝐧𝐝𝐢𝐚? Whether you're living in the US, UAE, UK, or Singapore; India continues to be a hotspot for wealth creation. But why do so many NRIs still invest here? Here’s why 👇 ✅ Higher Returns – Indian equity markets, mutual funds, and even fixed deposits offer attractive long-term returns. ✅ Tax-Free Income – Interest from NRE and FCNR deposits is tax-free in India. Plus, DTAA helps avoid double taxation. ✅ Currency Edge – You invest in INR, and with the right timing, your gains in foreign currency terms could be even higher. ✅ Diversification – Indian assets like gold, real estate, and stocks add balance to a global portfolio. ✅ Future Ready – Planning to return to India someday? Build your base early with property or retirement-focused investments. ✅ Emotional Roots – Beyond numbers, India is still home. 💡 Whether it’s for wealth creation, retirement planning, or building assets back home, India offers a solid mix of growth + stability...
Read more